The U.S. Food and Drug Administration late Thursday approved a new kind of drug to treat schizophrenia, a breakthrough after 70 years of incremental innovation that appears to avoid side effects ...

In my previous article, I discussed how AI is rapidly transforming the drug discovery process, significantly accelerating timelines and reducing costs. However, while AI's potential in this domain ...

Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach. By Ellen Barry and Christina Jewett The Food and Drug Administration on ...

By contrast, the new gene therapy only requires a single dose, and most patients in the study did not need to resume prophylactic factor IX treatments. "We hear from people born with hemophilia ...

Melatonin has been shown to be neuroprotective in different animal models of neonatal hypoxic–ischemic brain injury. However, its exact molecular mechanism of action remains unknown. Our aim was to ...

The synthetic version has been taken for more than 100 years and was initially released under the brand name Pitressin. The U.S. Food and Drug Administration (FDA) has licensed it under the brand name ...

Joseph Janes does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...

Despite this, there hasn’t been a new class of drug approved for the condition in nearly two decades. It’s a situation that in most other areas of medicine would be unacceptable, argued Nora ...

By Noah Weiland Noah Weiland has written about the public health policies that seek to address drug overdoses. Drug overdose deaths are decreasing sharply across the country, according to recent ...

The first dose, which is much smaller, prepares the immune system to respond more powerfully to the second, larger dose. This study, which was performed by bringing together computational modeling ...

The work resulted in liraglutide, the first long-lasting GLP-1-based drug, approved by the US Food and Drug Administration in 2010 for type 2 diabetes. In the meantime, researchers were already ...